Abstract | BACKGROUND: METHODS: A 1-year Markov model is used incorporating three health states: euthymic, manic and depressive. The model was populated using outcomes from a clinical trial on clinical efficacy and other published literature. RESULTS: The incremental cost-effectiveness ratio (ICER) per quality-adjusted life year (QALY) of ethyl-EPA in comparison with placebo was estimated to be -£2,782 in 2008/09 prices, the negative ICER indicating ethyl-EPA to be a more effective and less costly treatment option than placebo in terms of cost savings of other resource use. CONCLUSIONS: The sensitivity analysis indicated that the results were robust. Future research covering a longer time period using broader costs of the disease will be required to consolidate these findings.
|
Authors | Nadir Cheema, Sophia Frangou, Paul McCrone |
Journal | Therapeutic advances in psychopharmacology
(Ther Adv Psychopharmacol)
Vol. 3
Issue 2
Pg. 73-81
(Apr 2013)
ISSN: 2045-1253 [Print] England |
PMID | 24167678
(Publication Type: Journal Article)
|